DEUTSCHOVÁ, Barbora a Ivan REKTOR. Deep brain stimulation of the anterior nuclei of the thalamus in focal epilepsy. Clinical Neurophysiology. Clare: Elsevier Ireland, 2022, roč. 144, December 2022, s. 1-7. ISSN 1388-2457. Dostupné z: https://dx.doi.org/10.1016/j.clinph.2022.09.002.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Deep brain stimulation of the anterior nuclei of the thalamus in focal epilepsy
Autoři DEUTSCHOVÁ, Barbora (203 Česká republika, domácí) a Ivan REKTOR (203 Česká republika, garant, domácí).
Vydání Clinical Neurophysiology, Clare, Elsevier Ireland, 2022, 1388-2457.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30210 Clinical neurology
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.700
Kód RIV RIV/00216224:14110/22:00129377
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.clinph.2022.09.002
UT WoS 000886064800001
Klíčová slova anglicky Anterior thalamic nuclei; Focal epilepsy; Deep brain stimulation
Štítky 14110127, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 18. 1. 2023 12:36.
Anotace
Objective: To review the therapeutic effects of deep brain stimulation of the anterior nuclei of the thala-mus (ANT-DBS) and the predictors of its effectiveness, safety, and adverse effects. Methods: A comprehensive search of the medical literature (PubMed) was conducted to identify relevant articles investigating ANT-DBS therapy for epilepsy. Out of 332 references, 77 focused on focal epilepsies were reviewed. Results: The DBS effect is probably due to decreased synchronization of epileptic activity in the cortex. The potential mechanisms from cellular to brain network levels are presented. The ANT might participate actively in the network elaborating focal seizures. The effects of ANT-DBS differed in various studies; ANT-DBS was linked with a 41% seizure frequency reduction at 1 year, 69% at 5 years, and 75% at 7 years. The most frequently reported adverse effects, depression and memory impairment, were considered non -serious in the long-term follow-up view. ANT-DBS also has been used in a few cases to treat status epilep-ticus. Conclusions: We reviewed the clinical literature and identified several factors that may predict seizure outcome following DBS therapy. More large-scale trials are required since there is a need to explore stim-ulation settings, apply patient-tailored therapy, and identify the presurgical predictors of patient response. Significance: A critical review of the published literature on ANT-DBS in focal epilepsy is presented. ANT-DBS mechanisms are not fully understood; possible explanations are provided. Biomarkers of ANT-DBS effectiveness may lead to patient-tailored therapy.
Návaznosti
GA21-25953S, projekt VaVNázev: Subkortikální jádra a kortikální funkce z perspektivy hluboké mozkové stimulace (Akronym: DBS3D)
Investor: Grantová agentura ČR, Subkortikální jádra a kortikální funkce z perspektivy hluboké mozkové stimulace
VytisknoutZobrazeno: 9. 7. 2024 13:50